MISSISSAUGA, ONTARIO--(Marketwired - Nov. 8, 2017) - KP Tissue Inc. (KPT) (TSX:KPT) reports the Q3 2017 financial and operational results of KPT and Kruger Products L.P. (KPLP). Kruger Products is Canada's leading manufacturer of quality tissue products for the Consumer market (Cashmere, Purex, SpongeTowels, Scotties, and White Swan) and the Away-From-Home market, and continues to grow in the U.S. Consumer tissue business with the White Cloud® brand and premium private label products. KPT currently holds a 16.0% interest in KPLP.
KPLP Q3 2017 Business and Financial Highlights
- Revenue increased by 7.5% to $336.3 million in Q3 2017 compared to Q3 2016
- Adjusted EBITDA was $39.4 million in Q3 2017 compared to $45.6 million in Q3 2016
- TAD Products sales and Adjusted EBITDA contribution continued to be strong, in line with previously set targets
- Successful start-up of new Paper Machine #8 and a new converting line in Crabtree, Quebec site
- Declared a quarterly dividend of $0.18 per share to be paid on January 15, 2018
"Third quarter results were in-line with our expectations, however they reflect the continued negative impact of rising pulp prices which have reached record levels, and also higher freight costs driven by the recent hurricanes in the southern U.S., said Mario Gosselin, CEO of KP Tissue and KPLP.
"Our new paper machine in Quebec started production during the third quarter, and as planned we incurred start-up costs. The project was completed on time and on budget, and we anticipate that it will positively contribute to our Away-from-Home business starting in the first quarter of Fiscal 2018.
"The selling price increase announced in the Canadian market in July has started to take effect in the fourth quarter. Given the further escalation in pulp prices, Adjusted EBITDA for Q4 2017 is expected to decrease compared to Q4 2016 Adjusted EBITDA of $42.9 million," concluded Mr. Gosselin.
KPLP Q3 2017 Financial Results
Revenue in Q3 2017 was $336.3 million, compared to $312.8 million in Q3 2016, an increase of $23.5 million or 7.5%. The increase in revenue was primarily due to higher sales volume, partially offset by the unfavourable impact of foreign exchange on U.S. dollar sales.
Cost of sales in Q3 2017 increased to $290.8 million from $256.8 million in Q3 2016, primarily due to higher sales volumes, a significant increase in fibre costs, as well as higher freight costs and PM#8 project start-up costs, partially offset by the favourable impact of foreign exchange on U.S. dollar denominated costs. As a percentage of revenue, cost of sales were 86.5% in Q3 2017 compared to 82.1% in Q3 2016.
Selling, general and administrative (SG&A) expenses in Q3 2017 were $20.7 million, compared to $22.7 million in Q3 2016. The decrease was primarily due to the timing of spend and cost reduction initiatives. As a percentage of revenue, SG&A expenses were 6.2% in Q3 2017, compared to 7.3% in Q3 2016.
Adjusted EBITDA in Q3 2017 was $39.4 million, compared to $45.6 million in Q3 2016, lower by $6.2 million or 13.6%, primarily due to significantly higher fibre costs, increased freight costs, and start-up costs, partially offset by increased sales volume and lower SG&A costs.
Net income in Q3 2017 was $16.5 million, compared to $21.6 million in Q3 2016, primarily due to lower Adjusted EBITDA of $6.2 million and higher depreciation expense of $2.3 million. These items were partially offset by a change in foreign exchange gain of $2.0 million.
Total liquidity, representing cash and cash equivalents and availability under the credit line within covenant limitations, was $76.0 million as of September 24, 2017, compared to $80.3 million as of June 25, 2017.
KPT Q3 2017 Financial Results
KPT incurred a net loss of $0.1 million in Q3 2017. Included in the net loss was $2.6 million representing KPT's share of KPLP's income. The income was reduced by depreciation expense of $1.4 million related to adjustments to carrying amounts on acquisition and income tax expense of $1.3 million.
Dividends on Common Shares
The Board of Directors of KPT declared a quarterly dividend of $0.18 per share to be paid on January 15, 2018 to shareholders of record at the close of business on December 29, 2017.
Additional Information
For additional information please refer to Management's Discussion and Analysis (MD&A) of KPT and KPLP for the third quarter ended September 24, 2017 available on SEDAR at www.sedar.com or our website at www.kptissueinc.com.
Third Quarter Results Conference Call Information
KPT will hold its third quarter conference call on Wednesday, November 8, 2017 at 8:30 a.m. Eastern Time.
Via telephone: 1-877-223-4471 or 647-788-4922
Via the internet at: www.kptissueinc.com
Presentation material referenced during the conference call will be available at www.kptissueinc.com.
A rebroadcast of the conference call will be available until midnight, November 15, 2017 by dialing 800-585-8367 or 416-621-4642 and entering passcode 84517935.
The replay of the webcast will remain available on the website until midnight, November 15, 2017.
About KP Tissue Inc. (KPT)
KPT was created to acquire, and its business is limited to holding, a limited partnership interest in KPLP, which is accounted for as an investment on the equity basis. KPT currently holds a 16.0% interest in KPLP. For more information visit www.kptissueinc.com.
About Kruger Products L.P. (KPLP)
KPLP is Canada's leading manufacturer of quality tissue products for household, industrial and commercial use. KPLP serves the Canadian consumer market with such well-known brands as Cashmere®, Purex®, SpongeTowels®, Scotties® and White Swan®. In the U.S., KPLP manufactures the White Cloud® brand, as well as many private label products. The Away-From-Home division manufactures and distributes high-quality, cost-effective product solutions to a wide range of commercial and public entities. KPLP has approximately 2,500 employees and operates eight FSC® COC-certified (FSC® C-104904) production facilities in North America. For more information visit www.krugerproducts.ca.
Non-IFRS Measures
This press release uses certain non-IFRS financial measures which KPLP believes provide useful information to management of KPLP and the readers of the financial information in measuring the financial performance and financial condition of KPLP. These measures do not have a standardized meaning prescribed by IFRS and therefore may not be comparable to similarly titled measures presented by other companies. An example of such a measure is Adjusted EBITDA. Beginning with Q4 2015 in accordance with Canadian Securities Administrators Staff Notice 52-306 (Revised), we reference Adjusted EBITDA as a non-IFRS financial measure. This term replaces the previously referenced non-IFRS financial measure EBITDA. Our definition of Adjusted EBITDA is unchanged from our former definition of EBITDA. Accordingly, this change in terminology has no impact on our reported financial results for prior periods. Adjusted EBITDA is not a measurement of operating performance computed in accordance with IFRS and should not be considered as a substitute for operating income, net income or cash flows from operating activities computed in accordance with IFRS. "Adjusted EBITDA" is calculated by KPLP as net income (loss) before (i) interest expense, (ii) income taxes, (iii) depreciation, (iv) amortization, (v) impairment (gain on sale) of non-financial assets, (vi) loss (gain) on disposal of property, plant and equipment, (vii) foreign exchange loss (gain), (viii) costs related to restructuring activities, (ix) changes in amortized cost of Partnership units liability, and (x) one-time costs due to pension revaluations related to past service. A reconciliation of Adjusted EBITDA to the relevant reported results can be found in the MD&A of KPT and KPLP for the third quarter ended September 24, 2017 available on SEDAR at www.sedar.com.
Forward-Looking Statements
Certain statements in this press release about KPT's and KPLP's current and future plans, expectations and intentions, results, levels of activity, performance, goals or achievements or any other future events or developments constitute forward-looking statements. The words "may", "will", "would", "should", "could", "expects", "plans", "intends", "trends", "indications", "anticipates", "believes", "estimates", "predicts", "likely" or "potential" or the negative or other variations of these words or other comparable words or phrases, are intended to identify forward-looking statements. The forward-looking information is based on certain key expectations and assumptions made by KPT, including expectations and assumptions concerning: the impact of the TAD Project on Adjusted EBITDA; the expectation of continued growth in sales of TAD products in the U.S.; a successful ramp-up of the Crabtree paper machine; improved performance of the Away-From-Home business; and expanded distribution of White Cloud to select U.S. retailers. Although KPT believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information since no assurance can be given that such expectations and assumptions will prove to be correct.
The outlook provided in respect of Adjusted EBITDA for Q4 2017 is forward-looking information and is subject to the risk and uncertainties referred to below. The purpose of the outlook is to provide the reader with an indication of management's expectations, at the date of this press release, regarding KPLP's future financial performance. Readers are cautioned that this information may not be appropriate for other purposes.
Many factors could cause KPLP's actual results, level of activity, performance or achievements or future events or developments (which could in turn affect the economic benefits derived from the Corporation's economic interest in KPLP) to differ materially from those expressed or implied by the forward-looking statements, including, without limitation, the following factors, which are discussed in greater detail in the "Risk Factors - Risks Related to KPLP's Business" section of the KPT Annual Information Form dated March 9, 2017 available on SEDAR at www.sedar.com: Kruger Inc.'s influence over KPLP; KPLP's reliance on Kruger Inc.; consequences of an event of insolvency relating to Kruger Inc.; risks associated with the TAD Project; operational risks; Gatineau Plant land lease; significant increases in input costs; reduction in supply of fibre; increased pricing pressure and intense competition; KPLP's inability to innovate effectively; adverse economic conditions; dependence on key retail trade customers; damage to the reputation of KPLP or KPLP's brands; KPLP's sales being less than anticipated; KPLP's failure to implement its business and operating strategies; KPLP's obligation to make regular capital expenditures; KPLP's entering into unsuccessful acquisitions; KPLP's dependence on key personnel; KPLP's inability to retain its existing customers or obtain new customers; KPLP's loss of key suppliers; KPLP's failure to adequately protect its intellectual property rights; KPLP's reliance on third party intellectual property licenses; adverse litigation and other claims affecting KPLP; material expenditures due to comprehensive environmental regulation affecting KPLP's cash flow; KPLP's pension obligations are significant and can be materially higher than predicted if KPLP Management's underlying assumptions are incorrect; labour disputes adversely affecting KPLP's cost structure and KPLP's ability to run its plants; exchange rate and U.S. competitors; KPLP's inability to service all of its indebtedness; exposure to potential consumer product liability, restrictive covenants; interest rate and refinancing risk; information technology; cyber-security; insurance; internal controls; and trade related risk.
Readers should not place undue reliance on forward-looking statements made herein. The forward-looking information contained herein is expressly qualified in its entirety by this cautionary statement. The forward-looking information contained herein is made as of the date of press release and KPT undertakes no obligation to publicly update such forward-looking information to reflect new information, subsequent or otherwise, unless required by applicable securities laws.
| Kruger Products L.P. | ||||||
| Unaudited Condensed Consolidated Statement of Financial Position | ||||||
| (thousands of Canadian dollars) | ||||||
| September 24, 2017 | December 31, 2016 | |||||
| $ | $ | |||||
| Assets | ||||||
| Current assets | ||||||
| Cash and cash equivalents | 26,997 | 36,511 | ||||
| Trade and other receivables | 126,591 | 123,095 | ||||
| Receivables from related parties | 69 | 185 | ||||
| Advances to partners | 6,417 | 5,465 | ||||
| Inventories | 174,003 | 179,543 | ||||
| Income tax recoverable | 293 | 423 | ||||
| Prepaid expenses | 10,503 | 7,286 | ||||
| 344,873 | 352,508 | |||||
| Non-current assets | ||||||
| Property, plant and equipment | 748,458 | 762,270 | ||||
| Other long-term assets | 6,150 | 6,075 | ||||
| Goodwill | 160,939 | 160,939 | ||||
| Intangible assets | 14,955 | 15,270 | ||||
| Deferred income taxes | 33,359 | 39,913 | ||||
| Total assets | 1,308,734 | 1,336,975 | ||||
| Liabilities | ||||||
| Current liabilities | ||||||
| Bank indebtedness | - | 9,007 | ||||
| Trade and other payables | 196,459 | 201,477 | ||||
| Payables to related parties | 5,089 | 3,606 | ||||
| Income tax payable | 592 | 1,779 | ||||
| Distributions payable | 10,324 | 10,148 | ||||
| Current portion of provisions | 757 | 1,885 | ||||
| Current portion of long-term debt | 186,695 | 8,859 | ||||
| 399,916 | 236,761 | |||||
| Non-current liabilities | ||||||
| Long-term debt | 238,487 | 415,379 | ||||
| Provisions | 6,969 | 6,487 | ||||
| Pensions | 112,671 | 92,646 | ||||
| Post-retirement benefits | 57,881 | 57,162 | ||||
| Liabilities to non-unitholders | 815,924 | 808,435 | ||||
| Current portion of Partnership units liability | 5,571 | 8,611 | ||||
| Long-term portion of Partnership units liability | 135,903 | 137,296 | ||||
| Total Partnership units liability | 141,474 | 145,907 | ||||
| Total liabilities | 957,398 | 954,342 | ||||
| Equity | ||||||
| Partnership units | 351,381 | 336,576 | ||||
| Deficit | (61,775 | ) | (42,792 | ) | ||
| Accumulated other comprehensive income | 61,730 | 88,849 | ||||
| Total equity | 351,336 | 382,633 | ||||
| Total equity and liabilities | 1,308,734 | 1,336,975 | ||||
| Kruger Products L.P. | |||||||||||||
| Unaudited Condensed Consolidated Statement of Comprehensive Income (Loss) | |||||||||||||
| (thousands of Canadian dollars) | |||||||||||||
| 3-month period ended September 24, 2017 |
3-month period ended September 25, 2016 |
9-month period ended September 24, 2017 |
9-month period ended September 25, 2016 |
||||||||||
| $ | $ | $ | $ | ||||||||||
| Revenue | 336,284 | 312,823 | 939,943 | 888,270 | |||||||||
| Expenses | |||||||||||||
| Cost of sales | 290,777 | 256,823 | 802,108 | 747,348 | |||||||||
| Selling, general and administrative expenses | 20,726 | 22,645 | 66,467 | 66,283 | |||||||||
| Gain on sale of non-financial assets | (12 | ) | (395 | ) | (80 | ) | (395 | ) | |||||
| Restructuring costs, net | (245 | ) | 25 | (234 | ) | 418 | |||||||
| Operating income | 25,038 | 33,725 | 71,682 | 74,616 | |||||||||
| Interest expense | 10,533 | 11,192 | 31,554 | 33,327 | |||||||||
| Other (income) expense | (2,103 | ) | 813 | 1,860 | (307 | ) | |||||||
| Income before income taxes | 16,608 | 21,720 | 38,268 | 41,596 | |||||||||
| Income taxes | 158 | 162 | 4,922 | 1,612 | |||||||||
| Net income for the period | 16,450 | 21,558 | 33,346 | 39,984 | |||||||||
| Other comprehensive loss | |||||||||||||
| Items that will not be reclassified to net income: | |||||||||||||
| Remeasurements of pensions | (5,424 | ) | (20,097 | ) | (20,647 | ) | (63,986 | ) | |||||
| Remeasurements of post-retirement benefits | 2,929 | (2,885 | ) | (272 | ) | (4,519 | ) | ||||||
| Items that may be subsequently reclassified to net income: | |||||||||||||
| Available-for-sale investment | - | - | - | (290 | ) | ||||||||
| Cumulative translation adjustment | (23,774 | ) | 3,969 | (27,119 | ) | (16,858 | ) | ||||||
| Total other comprehensive loss for the period | (26,269 | ) | (19,013 | ) | (48,038 | ) | (85,653 | ) | |||||
| Comprehensive income (loss) for the period | (9,819 | ) | 2,545 | (14,692 | ) | (45,669 | ) | ||||||
| Kruger Products L.P. | |||||||||||||
| Unaudited Condensed Consolidated Statement of Cash Flows | |||||||||||||
| (thousands of Canadian dollars) | |||||||||||||
| 3-month period ended September 24, 2017 |
3-month period ended September 25, 2016 |
9-month period ended September 24, 2017 |
9-month period ended September 25, 2016 |
||||||||||
| $ | $ | $ | $ | ||||||||||
| Cash flows from (used in) operating activities | |||||||||||||
| Net income for the period | 16,450 | 21,558 | 33,346 | 39,984 | |||||||||
| Items not affecting cash | |||||||||||||
| Depreciation | 14,350 | 12,007 | 38,414 | 33,775 | |||||||||
| Amortization | 286 | 296 | 775 | 876 | |||||||||
| Gain on sale of property, plant and equipment | - | - | (2 | ) | (3 | ) | |||||||
| Change in amortized cost of Partnership units liability | (882 | ) | - | 4,178 | 1,234 | ||||||||
| Gain on sale of investment | - | - | - | (324 | ) | ||||||||
| Foreign exchange (gain) loss | (1,221 | ) | 813 | (2,318 | ) | (1,217 | ) | ||||||
| Interest expense | 10,533 | 11,192 | 31,554 | 33,327 | |||||||||
| Pension and post retirement benefits | 2,513 | 2,487 | 7,539 | 7,805 | |||||||||
| Provisions | (127 | ) | 392 | 211 | 1,191 | ||||||||
| Income taxes | 158 | 162 | 4,922 | 1,612 | |||||||||
| Gain on sale of non-financial assets | (12 | ) | (395 | ) | (80 | ) | (395 | ) | |||||
| Total items not affecting cash | 25,598 | 26,954 | 85,193 | 77,881 | |||||||||
| Net change in non-cash working capital | 5,130 | (6,009 | ) | (25,959 | ) | (10,471 | ) | ||||||
| Contributions to pension and post-retirement benefit plans | (3,735 | ) | (2,613 | ) | (11,406 | ) | (13,918 | ) | |||||
| Provisions paid | (565 | ) | (334 | ) | (1,015 | ) | (1,452 | ) | |||||
| Income tax payments | (115 | ) | (514 | ) | (3,169 | ) | (1,887 | ) | |||||
| Net cash from operating activities | 42,763 | 39,042 | 76,990 | 90,137 | |||||||||
| Cash flows from (used in) investing activities | |||||||||||||
| Purchases of property, plant and equipment | (12,033 | ) | (19,965 | ) | (50,278 | ) | (58,666 | ) | |||||
| Capitalized interest paid | (116 | ) | - | (497 | ) | - | |||||||
| Proceeds on sale of investment | - | - | - | 1,439 | |||||||||
| Government assistance received | 923 | - | 3,872 | 1,209 | |||||||||
| Purchases of software | (460 | ) | - | (460 | ) | (71 | ) | ||||||
| Proceeds on sale of property, plant and equipment | 14 | 535 | 1,184 | 539 | |||||||||
| Net cash used in investing activities | (11,672 | ) | (19,430 | ) | (46,179 | ) | (55,550 | ) | |||||
| Cash flows from (used in) financing activities | |||||||||||||
| Proceeds from long-term debt | (5,893 | ) | 4,204 | 20,877 | 4,995 | ||||||||
| Repayment of long-term debt | (4,749 | ) | (596 | ) | (5,250 | ) | (8,106 | ) | |||||
| Payment of deferred financing fees | - | (376 | ) | (12 | ) | (711 | ) | ||||||
| Interest paid on long-term debt | (7,819 | ) | (8,538 | ) | (18,930 | ) | (18,294 | ) | |||||
| Distributions and advances paid, net | (8,263 | ) | (4,806 | ) | (25,992 | ) | (16,883 | ) | |||||
| Net cash used in financing activities | (26,724 | ) | (10,112 | ) | (29,307 | ) | (38,999 | ) | |||||
| Effect of exchange rate changes on cash and cash equivalents held in foreign currency | (1,924 | ) | (80 | ) | (2,011 | ) | (1,519 | ) | |||||
| Increase (decrease) in cash and cash equivalents during the period | 2,443 | 9,420 | (507 | ) | (5,931 | ) | |||||||
| Cash and cash equivalents - Beginning of period | 24,554 | 10,104 | 27,504 | 25,455 | |||||||||
| Cash and cash equivalents - End of period | 26,997 | 19,524 | 26,997 | 19,524 | |||||||||
| Kruger Products L.P. | |||||||||||||
| Segment and Geographic Results | |||||||||||||
| (thousands of Canadian dollars) | |||||||||||||
| 3-month period ended September 24, 2017 |
3-month period ended September 25, 2016 |
9-month period ended September 24, 2017 |
9-month period ended September 25, 2016 |
||||||||||
| $ | $ | $ | $ | ||||||||||
| Segment Information | |||||||||||||
| Segment Revenue | |||||||||||||
| Consumer | 272,917 | 248,792 | 763,996 | 708,868 | |||||||||
| AFH | 62,497 | 59,411 | 171,090 | 167,513 | |||||||||
| Other | 870 | 4,620 | 4,857 | 11,889 | |||||||||
| Total segment revenue | 336,284 | 312,823 | 939,943 | 888,270 | |||||||||
| Segment Adjusted EBITDA | |||||||||||||
| Consumer | 38,077 | 42,907 | 105,951 | 104,433 | |||||||||
| AFH | 1,852 | 2,425 | 4,840 | 4,230 | |||||||||
| Other | (512 | ) | 326 | (236 | ) | 948 | |||||||
| Total segment Adjusted EBITDA | 39,417 | 45,658 | 110,555 | 109,611 | |||||||||
| Reconciliation to Net Income: | |||||||||||||
| Depreciation and amortization | 14,636 | 12,303 | 39,189 | 34,651 | |||||||||
| Interest expense | 10,533 | 11,192 | 31,554 | 33,327 | |||||||||
| Change in amortized cost of Partnership units liability | (882 | ) | - | 4,178 | 1,234 | ||||||||
| Gain on sale of property, plant and equipment | - | - | (2 | ) | (3 | ) | |||||||
| Gain on sale of non-financial assets | (12 | ) | (395 | ) | (80 | ) | (395 | ) | |||||
| Restructuring costs, net | (245 | ) | 25 | (234 | ) | 418 | |||||||
| Foreign exchange (gain) loss | (1,221 | ) | 813 | (2,318 | ) | (1,217 | ) | ||||||
| Income before income taxes | 16,608 | 21,720 | 38,268 | 41,596 | |||||||||
| Income taxes | 158 | 162 | 4,922 | 1,612 | |||||||||
| Net income | 16,450 | 21,558 | 33,346 | 39,984 | |||||||||
| Geographic Revenue | |||||||||||||
| Canada | 209,289 | 195,186 | 570,949 | 539,221 | |||||||||
| U.S. | 113,157 | 105,114 | 332,710 | 311,517 | |||||||||
| Mexico | 13,838 | 12,523 | 36,284 | 37,532 | |||||||||
| Total revenue | 336,284 | 312,823 | 939,943 | 888,270 | |||||||||
| KP Tissue Inc. | |||||||
| Unaudited Condensed Statement of Financial Position | |||||||
| (thousands of Canadian dollars) | |||||||
| September 24, 2017 | December 31, 2016 | ||||||
| $ | $ | ||||||
| Assets | |||||||
| Current assets | |||||||
| Distributions receivable | 1,653 | 1,636 | |||||
| Receivable from Partnership | - | 426 | |||||
| Income tax recoverable | 1,031 | - | |||||
| 2,684 | 2,062 | ||||||
| Non-current assets | |||||||
| Investment in associate | 104,650 | 117,349 | |||||
| Total Assets | 107,334 | 119,411 | |||||
| Liabilities | |||||||
| Current liabilities | |||||||
| Dividend payable | 1,653 | 1,636 | |||||
| Payable to Partnership | 52 | - | |||||
| Advances from Partnership | 1,040 | 914 | |||||
| Income tax payable | - | 884 | |||||
| 2,745 | 3,434 | ||||||
| Non-current liabilities | |||||||
| Deferred income taxes | 1,946 | 893 | |||||
| Total liabilities | 4,691 | 4,327 | |||||
| Equity | |||||||
| Common shares | 14,573 | 13,176 | |||||
| Contributed surplus | 144,819 | 144,819 | |||||
| Deficit | (67,862 | ) | (58,729 | ) | |||
| Accumulated other comprehensive income | 11,113 | 15,818 | |||||
| Total equity | 102,643 | 115,084 | |||||
| Total liabilities and equity | 107,334 | 119,411 | |||||
| KP Tissue Inc. | ||||||||||||||
| Unaudited Condensed Statement of Comprehensive Loss | ||||||||||||||
| (thousands of Canadian dollars, except share and per share amounts) | ||||||||||||||
| 3-month period ended September 24, 2017 |
3-month period ended September 25, 2016 |
9-month period ended September 24, 2017 |
9-month period ended September 25, 2016 |
|||||||||||
| $ | $ | $ | $ | |||||||||||
| Equity income | 1,179 | 2,010 | 931 | 2,101 | ||||||||||
| Dilution gain | 39 | 58 | 136 | 142 | ||||||||||
| Income before income taxes | 1,218 | 2,068 | 1,067 | 2,243 | ||||||||||
| Income taxes | 1,288 | 1,299 | 2,288 | 3,557 | ||||||||||
| Net income (loss) for the period | (70 | ) | 769 | (1,221 | ) | (1,314 | ) | |||||||
| Other comprehensive loss | ||||||||||||||
| net of tax expense (recovery) | ||||||||||||||
| Items that will not be reclassified to net income (loss): | ||||||||||||||
| Remeasurements of pensions | (755 | ) | (2,825 | ) | (2,885 | ) | (9,034 | ) | ||||||
| Remeasurements of post-retirement benefits | 287 | (285 | ) | (27 | ) | (447 | ) | |||||||
| Items that may be subsequently reclassified to net income (loss): | ||||||||||||||
| Available-for-sale investment | - | - | - | (41 | ) | |||||||||
| Cumulative translation adjustment | (4,086 | ) | 711 | (4,705 | ) | (3,495 | ) | |||||||
| Total other comprehensive loss for the period | (4,554 | ) | (2,399 | ) | (7,617 | ) | (13,017 | ) | ||||||
| Comprehensive loss for the period | (4,624 | ) | (1,630 | ) | (8,838 | ) | (14,331 | ) | ||||||
| Basic earnings (loss) per share | (0.01 | ) | 0.08 | (0.13 | ) | (0.15 | ) | |||||||
| Weighted average number of shares outstanding | 9,176,138 | 9,051,321 | 9,146,312 | 9,021,008 | ||||||||||
| KP Tissue Inc. | |||||||||||||
| Unaudited Condensed Statement of Cash Flows | |||||||||||||
| (thousands of Canadian dollars) | |||||||||||||
| 3-month period ended September 24, 2017 |
3-month period ended September 25, 2016 |
9-month period ended September 24, 2017 |
9-month period ended September 25, 2016 |
||||||||||
| $ | $ | $ | $ | ||||||||||
| Cash flows from (used in) operating activities | |||||||||||||
| Net income (loss) for the period | (70 | ) | 769 | (1,221 | ) | (1,314 | ) | ||||||
| Items not affecting cash | |||||||||||||
| Equity income | (1,179 | ) | (2,010 | ) | (931 | ) | (2,101 | ) | |||||
| Dilution gain | (39 | ) | (58 | ) | (136 | ) | (142 | ) | |||||
| Income taxes | 1,288 | 1,299 | 2,288 | 3,557 | |||||||||
| Total items not affecting cash | 70 | (769 | ) | 1,221 | 1,314 | ||||||||
| Net change in non-cash working capital | (219 | ) | - | 478 | - | ||||||||
| Tax payments | (225 | ) | - | (1,999 | ) | (205 | ) | ||||||
| Tax Distribution received | - | - | 481 | - | |||||||||
| Advances received | 444 | - | 1,040 | 205 | |||||||||
| Net cash from (used in) operating activities | - | - | - | - | |||||||||
| Cash flows from investing activites | |||||||||||||
| Partnership unit distributions received | 1,218 | 1,180 | 3,586 | 3,728 | |||||||||
| Net cash from investing activities | 1,218 | 1,180 | 3,586 | 3,728 | |||||||||
| Cash flows used in financing activities | |||||||||||||
| Dividends paid | (1,218 | ) | (1,180 | ) | (3,586 | ) | (3,728 | ) | |||||
| Net cash used in financing activities | (1,218 | ) | (1,180 | ) | (3,586 | ) | (3,728 | ) | |||||
| Increase (decrease) in cash and cash equivalents during the period | - | - | - | - | |||||||||
| Cash and cash equivalents - Beginning of period | - | - | - | - | |||||||||
| Cash and cash equivalents - End of period | - | - | - | - | |||||||||
Contact Information:
Francois Paroyan
General Counsel and Corporate Secretary
KP Tissue Inc.
905.812.6936
francois.paroyan@krugerproducts.ca
INVESTORS:
Mike Baldesarra
Director of Investor Relations
KP Tissue Inc.
905.812.6962
IR@KPTissueinc.com